SCHEMBL5621140

SCHEMBL5621140

CCOC(=O)CC(=O)c1cccc(I)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC2 Q92769 2/20 0.50
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 1/20 0.50
GRM5 P41594 1/20 0.43
MGAM O43451 1/20 0.42
GAA P10253 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
TP53BP1 Q12888 1/20 0.42
SYK P43405 1/20 0.40
NLRP3 Q96P20 2/20 0.40
TSHR P16473 2/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
NPC1 O15118 1/20 0.40
HDAC3 O15379 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2958248 0.85 ALDH1A1 (0.54) HDAC1HDAC2ALDH1A1GRM5GAA
SCHEMBL1167294 0.84 KMT2A (0.53) KMT2AMEN1ALDH1A1KDM4EHDAC8
SCHEMBL290760 0.83 RXFP1 (0.52) KMT2AMEN1ALDH1A1KDM4ETSHR
SCHEMBL29902970 0.83 KDM4E (0.51) KMT2AMEN1ALDH1A1KDM4EMGAM
SCHEMBL11772465 0.83 KDM4E (0.51) KMT2AMEN1ALDH1A1KDM4EMGAM
SCHEMBL1167035 0.81 NPC1 (0.55) KMT2AMEN1HDAC1ALDH1A1KDM4E
SCHEMBL1167517 0.81 ERCC5 (0.58) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL4628989 0.81 KMT2A (0.50) KMT2AMEN1ALDH1A1KDM4EHDAC8
SCHEMBL4206161 0.81 KDM4E (0.54) KMT2AMEN1ALDH1A1KDM4ETSHR
SCHEMBL13249005 0.81 KDM4E (0.50) KMT2AMEN1ALDH1A1KDM4EMGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2822940-B1 NOVEL COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES CADILA HEALTHCARE LTD (IN) 2017-02-15 EP claimed
US-9273041-B2 Compounds for the treatment of dyslipidemia and related diseases CADILA HEALTHCARE LIMITED (IN) 2016-03-01 US claimed
US-20150099696-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES CADILA HEALTHCARE LIMITED (IN) 2015-04-09 US claimed
EP-2822940-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES Cadila Healthcare Limited (IN) 2015-01-14 EP claimed
WO-2013132509-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES CADILA HEALTHCARE LIMITED (IN) 2013-09-12 WO claimed
US-20220324814-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS INC (US) 2022-10-13 US disclosed
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 US disclosed
CN-105980386-B Pyrazolo compounds and uses thereof 基因泰克公司 2021-08-13 CN disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 US disclosed
US-10894776-B2 2021-01-19 US disclosed
US-20200123114-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2020-04-23 US disclosed
EP-2970307-B1 PYRAZOLO COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2020-03-11 EP disclosed
US-20140066404-A1 PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND COMPOSITION FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS CONTAINING SAME EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2014-03-06 US disclosed
US-8604210-B2 Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2013-12-10 US disclosed
WO-2013131931-A1 AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY COMPOUND HANDLING B.V. (NL) 2013-09-12 WO disclosed
WO-2013132509-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES CADILA HEALTHCARE LIMITED (IN) 2013-09-12 WO disclosed
US-20120220550-A1 PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND COMPOSITION FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS CONTAINING SAME EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) 2012-08-30 US disclosed
US-7169797-B2 Protein-tyrosine phosphatase inhibitors and uses thereof ABBOTT LABORATORIES (US) 2007-01-30 US disclosed
US-20040214870-A1 Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; 5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid ABBVIE INC. 2004-10-28 US disclosed
US-20040167188-A1 Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; ABBOTT LABORATORIES 2004-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123114-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF CAPNS1, CAPN9, CAPN1 KMT2A 4418/4885MEN1 4845/4885HDAC1 517/4885
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 KMT2A 4418/4885MEN1 4845/4885HDAC1 517/4885
US-10894776-B2 CAPNS1, CAPN9, CAPN2 KMT2A 4469/4885MEN1 4832/4885HDAC1 568/4885
US-20150099696-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES PCSK9, LIPC, LCAT KMT2A 3673/4885MEN1 1538/4885HDAC1 1056/4885
US-20120220550-A1 PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND COMPOSITION FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS CONTAINING SAME PTH1R, VDR, SOST KMT2A 3628/4885MEN1 1308/4885HDAC1 607/4885
US-20140066404-A1 PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND COMPOSITION FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS CONTAINING SAME PTH1R, VDR, SOST KMT2A 3628/4885MEN1 1308/4885HDAC1 607/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 KMT2A 4418/4885MEN1 4845/4885HDAC1 517/4885
US-20220324814-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF CAPNS1, CAPN9, CAPN1 KMT2A 4418/4885MEN1 4845/4885HDAC1 517/4885
US-20040167188-A1 Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; G6PC1, PPP1R1B, PPP1R7 KMT2A 2609/4885MEN1 2107/4885HDAC1 216/4885
US-20040214870-A1 Controlling gene expression; antidiabetic agents; insulin resistance; autoimmune disease; 5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid G6PC1, PPP1R7, PPP1R1B KMT2A 2348/4885MEN1 3309/4885HDAC1 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.